Karin Jordan1, Iris Kinitz2, Wieland Voigt2, Timo Behlendorf2, Hans-Heinrich Wolf2, Hans-Joachim Schmoll2. 1. Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle/Wittenberg, Ernst-Grube-Str. 40, 06120 Halle, Saale, Germany. Electronic address: karin.jordan@medizin.uni-halle.de. 2. Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle/Wittenberg, Ernst-Grube-Str. 40, 06120 Halle, Saale, Germany.
Abstract
AIM OF THE STUDY: In multiple-day chemotherapy (MDC), the combination of a 5-HT(3)-antagonist plus dexamethasone is still a standard of care. The role of a NK-1-antagonist remains to be defined. PATIENTS AND METHODS: Seventy eight cancer patients undergoing multiple-day chemotherapy of high (HEC) or moderate (MEC) emetic risk received granisetron, dexamethasone plus aprepitant during chemotherapy. After the end of chemotherapy, aprepitant plus dexamethasone was given for another 2 days. Primary end-point was complete response (CR) in the overall phase (day 1 until 5 days after the end of chemotherapy). RESULTS: Thirty eight patients underwent HEC and 40 patients underwent MEC for a median of 3.5 days. CR was seen in 57.9% and 72.5% of patients receiving HEC and MEC, respectively. The tolerability of the aprepitant regimen over 5-7 days was comparable with a 3-day aprepitant regimen. CONCLUSIONS: This is the first report in MDC with a NK-1-antagonist containing antiemetic regimen showing a favourable safety profile with good antiemetic efficacy.
AIM OF THE STUDY: In multiple-day chemotherapy (MDC), the combination of a 5-HT(3)-antagonist plus dexamethasone is still a standard of care. The role of a NK-1-antagonist remains to be defined. PATIENTS AND METHODS: Seventy eight cancerpatients undergoing multiple-day chemotherapy of high (HEC) or moderate (MEC) emetic risk received granisetron, dexamethasone plus aprepitant during chemotherapy. After the end of chemotherapy, aprepitant plus dexamethasone was given for another 2 days. Primary end-point was complete response (CR) in the overall phase (day 1 until 5 days after the end of chemotherapy). RESULTS: Thirty eight patients underwent HEC and 40 patients underwent MEC for a median of 3.5 days. CR was seen in 57.9% and 72.5% of patients receiving HEC and MEC, respectively. The tolerability of the aprepitant regimen over 5-7 days was comparable with a 3-day aprepitant regimen. CONCLUSIONS: This is the first report in MDC with a NK-1-antagonist containing antiemetic regimen showing a favourable safety profile with good antiemetic efficacy.
Authors: I N Olver; P Grimison; M Chatfield; M R Stockler; G C Toner; V Gebski; R Harrup; C Underhill; G Kichenadasse; N Singhal; I D Davis; A Boland; A McDonald; D Thomson Journal: Support Care Cancer Date: 2012-12-30 Impact factor: 3.603
Authors: Petra Christine Feyer; Ernesto Maranzano; Alexander Molassiotis; Fausto Roila; Rebecca A Clark-Snow; Karin Jordan Journal: Support Care Cancer Date: 2010-08-10 Impact factor: 3.603
Authors: Paul J Hesketh; Matti Aapro; Karin Jordan; Lee Schwartzberg; Snezana Bosnjak; Hope Rugo Journal: Biomed Res Int Date: 2015-09-03 Impact factor: 3.411